Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Gerstner ER, et al. Among authors: plotkin sr. Clin Cancer Res. 2020 Jan 1;26(1):206-212. doi: 10.1158/1078-0432.CCR-19-1739. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558474 Free PMC article.
Primary nervous-system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Lancet Oncol. 2001 Jun;2(6):354-65. doi: 10.1016/S1470-2045(00)00390-9. Lancet Oncol. 2001. PMID: 11905752 Review.
Primary nervous system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Curr Treat Options Oncol. 2002 Dec;3(6):525-35. doi: 10.1007/s11864-002-0071-7. Curr Treat Options Oncol. 2002. PMID: 12392641 Review.
Peripheral and cranial nerve sheath tumors.
Mrugala MM, Batchelor TT, Plotkin SR. Mrugala MM, et al. Among authors: plotkin sr. Curr Opin Neurol. 2005 Oct;18(5):604-10. doi: 10.1097/01.wco.0000179507.51647.02. Curr Opin Neurol. 2005. PMID: 16155448 Review.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021. Cancer Cell. 2007. PMID: 17222792 Free PMC article. Clinical Trial.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Batchelor TT, et al. Among authors: plotkin sr. J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458050 Free PMC article. Clinical Trial.
200 results